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Abstract The aim of our paper is to highlight the main therapeutic principles and the management 
options in the case of a diabetic patient who has had a sudden hearing loss. Mainly, the aim is to 
underline the sudden hearing loss treatment adjustment of the diabetic patient compared to the 
non-diabetic patient. 
By understanding the mechanism of sudden hearing loss in a diabetic patient, namely the 
impact of glycemic variations and their implication on the microvascular structures of the inner 
ear, we try to underline the treatment principles and management options of the previously 
mentioned combined pathologies. 
Thus, it is necessary to adapt the classes of drugs used in the case of sudden sensorineural 
hearing loss of the diabetic patient in comparison with the non-diabetic patient, in order not to 
aggravate or complicate the patient’s functional status. Therefore, the treatment will need to be 
adapted both by classes of medication and by the type of administration used. 
Adequate control of the progression, treatment and complications of diabetes mellitus ensures 
optimal treatment management in case of a sudden hearing loss and therefore interferes with the 
favorable functional hearing outcomes. 
The role of this paper is not only to state the therapeutic principles in the case of sudden 
hearing loss in a diabetic patient, but also to analyze the impact on the management of potential 
local and systemic risk factors. 
Keywords  sudden hearing loss, sensorineural hearing loss, diabetes mellitus, diabetic 
microangiopathy 
Highlights  The diabetic patient represents one of the challenges of current medicine, by the 
complexity of multiple organ disorders associated with this pathology, its evolution and 
treatment particularities. 
 Vasculopathies and neuropathies are frequent complications in the course of the illness 
and sudden hearing loss comes with significant damage to the quality of life. 
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Introduction 
Nowadays, one of the comorbidities that, if not 
adequately treated, have an increased potential for 
developing complex and extensive complications is 
known to be diabetes mellitus (DM). This condition is one 
of the fastest developing chronic pathologies of the 
moment. 
Diabetes is a disease that involves a series of 
metabolic afflictions determined by modified insulin 
secretion and following the altered and adjusted actions of 
the previously mentioned hormone that defines a higher 
level of blood sugar. This metabolic damage may 
determine misuse of proteins, fats and carbohydrates that 
make the body readapt and create compensatory 
mechanisms to work by the new dictated parameters. 
Hyperglycemia, emerged as compensation for the new 
metabolic changes, determines the poor functioning of 
various systems and organs.  
Because the diabetic patient has either a severely 
deficient insulin production or the body is not capable of 
using the insulin produced by the pancreas, there are two 
main types of diabetes mellitus described in the literature.  
Type I Diabetes Mellitus is defined as the autoimmune 
destruction of the beta-cells within the pancreas, while the 
patients suffering from this condition are insulin-
dependent and need to pay attention to their glycemic 
values, to accurately control blood glucose levels during 
the day. This type of diabetes is found in children and 
adolescents. 
Type II Diabetes Mellitus is defined by an inadequate 
response of fat and muscle cells of the body to insulin and 
a compensatory production of insulin by the liver to try 
and dispute that improper response. This type of diabetes 
is typical in adults, frequently associated with obesity and 
may or may not be insulin-dependent, depending on the 
moment when diabetes is discovered.  
Thus, as diabetes progresses, it can lead to different 
complications such as nephropathy, neuropathy, 
oculopathy, microangiopathy and even heart conditions 
(1). 
A possible, but not so much discussed complication of 
this condition is hearing impairment and, usually, in the 
case of a diabetic patient, the hearing loss is bilateral, 
sensorineural, symmetrical and with a tendency of mainly 
affecting the low and mid frequencies.  
Specialty literature studies show that when discussing 
diabetic patients, they are more susceptible to developing 
sudden sensorineural hearing loss than non-diabetic 
patients, especially as a result of microvascular 
complications (2). 
This paper mainly aims to underline the sudden 
hearing loss treatment adjustments of the diabetic patient 
compared to the non-diabetic one. 
Discussions 
The sudden idiopathic hearing loss represents a form 
of acute hearing loss audiometrically expressed as a 
sensorineural hearing loss higher than 30dB, on three 
consecutive frequencies, with an onset of 
symptomatology of maximum 72 hours before the 
presentation of the patient to the ENT physician’s office. 
In most cases, it is unilateral, the prognosis of hearing 
recovery being often favorable. 
The pathogenic mechanism is not readily identifiable, 
since there are very few cases in which it is possible to 
tell with precision what hearing loss was caused by (3). 
Specialty literature mentions the involvement of 
infectious factors (viral or bacterial), vascular 
(hemorrhagic or ischemic), autoimmune (Cogan's disease, 
autoimmune thyroiditis, sarcoidosis, Wegener's 
granulomatosis), tumors (acoustic neurilemmoma which 
often causes slow progressive hearing loss without 
excluding a possible clinical onset in the form of sudden 
hearing loss), traumatic, chemical or toxic causes 
(ototoxic medication), etc. (4). Suddenly installed hearing 
loss is a medical emergency, although some literature 
studies have shown that, in some cases, hearing may 
improve even if no treatment is administered. 
Nevertheless, it is worth mentioning that the presence 
of other conditions such as hypertension, diabetes 
mellitus, dyslipidemias, and even the age of the patient, 
can lead to a bad response compared to patients who do 
not suffer from the previously mentioned conditions (5). 
These comorbidities directly or indirectly influence the 
appearance, evolution, responsiveness to treatment and 
prognosis of the sudden hearing loss (6). 
However, literature has not shown yet if the associated 
comorbidities and age influence, together or separately, 
the prognosis of patients who have sudden sensorineural 
hearing loss.  
An essential element to be mentioned is that diabetes, 
as well as other comorbidities, influence the therapeutic 
strategy that the patient needs to undertake, due to the 
certain possible complications that might occur and may 
or may not contraindicate specific therapies (7-9).  
Researchers investigated the prevalence of diabetes in 
patients with sudden idiopathic sensorineural hearing loss 
compared to a diabetic patient with normal hearing and 
revealed that it was almost double. It seems that through 
cerebral microangiopathy and due to diabetic changes in 
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blood viscosity, sudden idiopathic sensorineural hearing 
loss is mediated in a diabetic patient, although the proper 
mechanism which determines hearing loss has not been 
discovered yet (10). 
Several studies conducted on humans have shown the 
thickening of the capillary walls of the stria vascularis, the 
basilar membrane and the endolymphatic sac, 
atherosclerotic narrowing of the internal auditory artery, 
atrophy of the stria vascularis, loss of outer hair cells 
(OHCs) mainly in the lower basal cochlear turn, spiral 
ganglion neural atrophy, and VIII cranial nerve 
demyelination (11, 12). 
A rigorous anamnesis, as well as a detailed history of 
the disease, can provide important elements that will lead 
to a possible cause or triggering factor of the suddenly 
installed hearing loss. 
Practice guidelines strongly recommend the correct 
differentiation between sensorineural hearing loss 
(SNHL) and conductive hearing loss in patients who 
undergo an episode of sudden hearing loss (Figure 1). 
 
 
Figure 1. Left - Sensorineural hearing 
loss; Right - Conductive Hearing loss 
Several elements help establish a definite diagnosis in 
case of suddenly installed hearing loss: 
o Pure tone audiometry, vocal audiometry and 
acoustic immittance, which are routine audiometric tests; 
o Otoscopy to appreciate the local appearance of the 
external auditory meatus and the tympanic membrane and 
thus eliminate possible local causes that could determine 
sudden hearing loss; 
o Instrumental measuring of hearing acuity using a 
512Hz tuning fork that helps differentiate between 
sensorineural hearing loss and conductive hearing loss in 
an emergency room (bilateral positive Rinne, Weber 
lateralized in the healthy ear) (Figure 2.); 
 
Figure 2. 
512Hz tuning Fork 
o Brainstem auditory evoked potential that helps 
identify the possible lesional headquarters by studying the 
distinctions between ears in terms of the differences 
between the I-III and I-V intervals; 
o Magnetic Resonance Imaging using contrast medium 
is considered to be “the gold standard” method in 
identifying an acoustic neuroma, a labyrinthine 
hemorrhage, an inflammatory process or an 
endolymphatic hydrops; 
o Vestibular evaluation to complement the patient's 
clinical examination if there is vestibular symptomatology 
(vertigo, imbalance) in addition to hearing loss. In 
patients experiencing a vertiginous crisis, this 
examination should be performed at the head of the bed 
and involves the evaluation of nystagmus, oculomotricity, 
and the development of evidence to help differentiate 
between central and peripheral vertigo (13). 
The treatment administered in case of sudden hearing 
loss is non-specific and attempts to cover the possible 
pathogenic mechanisms involved. There are some 
treatment principles and options which are worth 
mentioning, but in the case of a diabetic patient, the 
essential element that always has to be taken into account 
when choosing and controlling the treatment and 
prognosis of a sudden idiopathic hearing loss is the blood 
glucose level. The treatment strategy is also influenced by 
the age of the patient, gender, body mass index, presence 
of tinnitus, dizziness, ear fullness sensation and presence 
of cerebral microangiopathy besides associated diseases 
(6, 10). 
Thus, here are the main therapeutic options used in the 
treatment of sudden idiopathic sensorineural hearing loss: 
Anti-inflammatory agents such as corticosteroids, 
whose role is to reduce perineural auditory and cochlear 
Andreea Rusescu et al. 
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inflammation, influencing any anti-inflammatory or 
immunosuppressive reaction and vascular permeability 
(14). This is the most common treatment used in sudden 
idiopathic sensorineural hearing loss, but it should never 
be used in high dosage therapy in case of diabetic 
patients, since it determines the increase of blood glucose 
levels and may lead to poor prognosis. A more extended 
treatment regarding the period of drug administration with 
lower dosage is preferable in diabetic patients compared 
to non-diabetic patients, in whose case higher dosage 
therapy is used.  Literature highlights the use of intra-
tympanic cortisone, but with low good outcomes 
compared to oral cortisone therapy (15). 
The use of Vasodilators such as Lipo-Prostaglandin 
E1 is justified by their ability to improve the blood flow 
to the cochlea and thus prevent local hypoxia. The 
duration of diabetes and the pre-existence of 
microvascular diabetic complications may compromise 
the use of these agents (16). 
Rheological agents are also used, since they improve 
oxygen flow by modifying blood viscosity through the 
use of low-molecular-weight dextrans, pentoxifylline or 
anticoagulants (heparin, warfarin). The use of these 
medications may cause hypoglycemia, so special care 
should be taken not to decompensate the patient's diabetes 
and to properly adjust the treatment of the associated 
conditions before initiating the treatment for the sudden 
hearing loss (9). 
Antiviral agents are used only if a viral cause is 
suspected. Literature describes a limited use of acyclovir 
and amantadine in the treatment of sudden idiopathic 
hearing loss. Taking into account that the diabetic patient 
has a compromised and irregular reactive immune system, 
the probability of contacting a viral infection increases, 
thus the idea of associating antiviral agents in the 
treatment of sudden idiopathic hearing loss in a diabetic 
patient is strongly recommended (9, 10). 
Diuretics or diuretic-like medication are used when 
there is a suspicion of endolymphatic hydrops, since these 
drugs can help reduce the fluid pressure load that can 
occur in the inner ear. They are helpful while trying to 
prevent an attack, but lack effectiveness in case of an 
already triggered attack. Diuretics or diuretic-like 
medication may decrease the effectiveness of the oral 
antidiabetic treatment (9). 
Supplementation with vitamin D can bring a modest 
benefit to the diabetic patient with hearing loss. The role 
of vitamin D is well known in chronic pathology and is 
now considered to be a vitamin-hormone with multiple 
beneficial actions. In most cases, the benefit is maximum 
if associated with magnesium. Vitamin D deficiency can 
lead to a degree of osteoporosis of the temporal bone, 
which will affect the transmission of sounds. Some 
studies even suggest supplementation with vitamin D 
intrapartum to prevent congenital deafness (17, 18). 
Hyperbaric oxygen therapy, if used since the early 
stages, can significantly improve hearing loss. Salvage 
therapy with hyperbaric oxygen results are compared in 
the literature with the results obtained by using 
corticosteroids, thus being considered an effective 
treatment option (19-21). 
Carbogen inhalation. This gas is composed of 95% 
Oxygen and 5% Carbon dioxide. It is believed that the 
administration of this combination of gases, will result in 
the vasodilation of the inner ear and increased blood flow 
and oxygen to the damaged hair cells that may encourage 
hearing loss recovery if a vascular disorder was the cause 
of it. The benefits of this therapy have been debated over 
the years, but ENT specialists have not reached a final 
decision yet. According to Kallinen et al., this inhalation 
therapy was proven to be more useful in patients with a 
low response on flat and high-pitched tones (22, 23). In a 
clinical analysis in 2004, Ni y. et al. concluded that drug 
therapy combined with Carbogen administration has 
better results in treating sudden hearing loss (24). Some 
authors suggest a five day-course of inhaler 
administration for an hour a day and others elect a shorter 
course of 3 days, but with a more intensive frequency: 10 
minutes every hour while the patient is awake. As Ni y. 
and others concluded that Carbogen use is an excellent 
adjuvant in the systemic drug treatment.  
Studies have shown that treatments for sudden 
idiopathic hearing loss based on the use of corticosteroids, 
i.e. lipo-Prostaglandin E1 and carbogen gas inhalation, are 
more effective than other treatment strategies studied and 
have great results even in patients with diabetes mellitus 
(25). 
Regarding the prognosis of suddenly installed hearing 
loss, its spontaneous recovery rate is generally good 
(approximately 47-63%, according to specialty studies), 
but depending on associated comorbidities, such as 
diabetes and its complications, as well as the onset of the 
treatment administered depending on the duration of 
diabetes, glycemic control and the onset of the sudden 
idiopathic hearing loss, it is associated with a lower 
recovery rate.  
It has been shown that the more severe the hearing 
loss, associated with a lack of proper diabetes control and/ 
or diabetic complications, the more unfavorable the 
prognosis. 
Hearing loss in a diabetic patient 
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Patients who do not fully recover hearing may be 
advised on the possibilities of hearing impairment 
depending on age, degree of hearing loss and associated 
comorbidities. 
Although in most cases, hearing loss associated with 
diabetes is bilateral, sensorineural, symmetrical and with 
a tendency of mainly affecting the low and mid 
frequencies, there are cases in which a sudden idiopathic 
sensorineural hearing loss can occur.  
A sudden idiopathic sensorineural hearing loss in a 
diabetic patient can have a bad onset with deep hearing 
loss compared to the case of a non-diabetic person, 
depending on blood glucose levels, pre-existent 
management and complications of diabetes and can also 
associate poor prognosis and recovery as well as lack of 
treatment compliance.  
Periodic and constant blood glucose level control 
helps adapt the treatment for hearing loss properly.  
The most effective medications for the treatment of 
sudden idiopathic sensorineural hearing loss in a diabetic 
patient are equally considered to be the corticosteroids, 
i.e. lipo-prostaglandin E1 and Carbogen gas inhalation.  
The availability of certain treatment options as well as 
the time passed between the patient’s presentation to the 
physician and the onset of hearing loss or the initiation of 
the treatment are important elements that dictate the 
prognosis of hearing recovery as well as the efficiency of 
the treatments of choice. Although, as previously 
described, there is a wide range of therapeutic options that 
can be used in the case of sudden idiopathic hearing loss, 
most of them ranked as non-specific, their availability and 
degree of applicability to each individual that must be 
treated are some of the major challenges of an ENT 
physician.  
Another important factor that dictates the prognosis 
and the good course of treatment is the patient’s 
reluctance towards some non-infusible or drug-staging 
treatments and, in the absence of appropriate medical 
knowledge or a good understanding of the effectiveness 
of these therapeutic options, they are categorized as 
unconventional by the patient and do not make him 
choose this specific treatment despite its availability, 
namely Carbogen gas inhalation or hyperbaric oxygen 
therapy. 
Diabetes belongs to a pathological field in which 
constant advances are made regarding the available 
therapies. As in other specialties, such as neurology, 
cardiology or oncology, on-going studies and research 
give us more and more options regarding the treatment of 
choice (26, 27). Especially in cases where diabetes is 
associated with other comorbidities, the therapy options 
are limited by the patient’s general condition and 
tolerance to aggressive treatments. 
Unfortunately, there is no international consensus 
regarding the treatment of sudden hearing loss. There are 
some American authors who recommend cortisone 
therapy for one month from the onset of hearing loss and 
there are some French authors who recommend cortisone 
therapy for 10 days from the onset of hearing loss. 
Moreover, there are differences of opinion regarding the 
proper moment for therapy initiation, given the moment 
of hearing loss occurrence. Some authors maintain the 
hypothesis of its important initiation in the first 24 to 72 
hours, while others allow initiation even up to 5-7 days 
after the onset of sudden hearing loss. We are talking 
about the existence of a high risk of malpractice and a 
questionable therapeutic attitude that depends on the 
clinical experience and constantly improved medical 
knowledge of the ENT physician. 
This lack of pre-established therapeutic protocols 
compared to other pathologies, such as cancer or any 
other well-known and classified disease in terms of 
staging and treatment options, creates a tendency of 
treatment adaptation at a national level, in relation with 
geographic, cultural and socio-economic factors.  
Conclusions 
Diabetes mellitus, as one of the fastest developing 
chronic pathologies of the moment, is defined by a group 
of metabolic disorders which could determine a complex 
series of complications that affect the eyes, kidneys, 
nervous system and peripheral blood vessels. 
Sudden idiopathic sensorineural hearing loss that 
occurs in patients with diabetes mellitus has been 
associated with more severe hearing loss and also with 
poor prognosis that could become irrecoverable in case no 
treatment is administered and it also regards the duration 
of diabetes, the onset of the hearing loss, as well as the 
presence or absence of diabetic comorbidities, the age of 
the patient and other associated conditions. 
Similarly, the post-prandial glucose level and the 
proper control of blood glucose levels are more likely to 
affect the evolution of the disease. 
Sudden idiopathic sensorineural hearing loss occurring 
in a patient with arterial hypertension, diabetes mellitus or 
dyslipidemia or in elderly patients, is associated with an 
increased prevalence of cerebral microangiopathy, 
highlighted by magnetic resonance imaging, and it 
determines a slower hearing recovery, as shown if 
following the improvements in speech discrimination 
tests. 
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